Ontology highlight
ABSTRACT: Background
HER2-targeted therapies have revolutionized the treatment of HER2-positive breast cancer patients, leading to significant improvements in tumor response rates and survival. However, resistance and incomplete response remain considerable challenges. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a novel therapeutic strategy for the management of dyslipidemia by enhancing the clearance of low-density lipoprotein cholesterol receptors, however recent evidence also shows links between PCSK9 and cancer cells. We present an innovative immunization approach combining capsid virus-like particle (cVLP)-based vaccines against HER2 and PCSK9.Methods
The therapeutic activity of the combined vaccine was evaluated in female mice challenged with HER2-positi
SUBMITTER: Scalambra L
PROVIDER: S-EPMC11784117 | biostudies-literature | 2025 Jan
REPOSITORIES: biostudies-literature